Outlook Therapeutics, Inc.
OTLKNASDAQHealthcare● Active
$0.72
$-0.05(-7.04%)
Market Cap$29703369
P/E Ratio—
52W High$3.39
52W Low$0.161
Outlook Therapeutics, Inc. (OTLK) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OTLK · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.16
Est. -$0.12 · -33.3%
Revenue
$0.00B
Est. $0.00B · -97.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
OTLK reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.20
Rev. $3.00B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.20
Rev. Est.$3.00B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.11 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.12 | -$0.16 | -33.3% | $0.00B | $0.00B | -97.1% |
| ▼ Q1 FY2026 | Feb 17, 2026 | -$0.17 | -$0.22 | -29.4% | $-0.00B | $0.00B | -138.4% |
| ▲ Q4 FY2025 | Dec 19, 2025 | -$0.26 | -$0.22 | +15.4% | $-0.00B | $0.01B | -101.6% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.42 | -$0.44 | -4.8% | $0.00B | $0.01B | -74.3% |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.55 | -$0.40 | +27.3% | — | $0.00B | — |
| ▼ Q1 FY2025 | Feb 14, 2025 | -$0.85 | -$0.89 | -4.7% | — | $0.00B | — |
| ▲ Q4 FY2024 | Dec 27, 2024 | -$0.83 | -$0.77 | +7.2% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.11
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$0.16
EPS Est.
-$0.12
EPS Surpr.
-33.3%
Revenue
$0.00B
Q1 FY2026
Feb 17, 2026Miss
EPS Actual
-$0.22
EPS Est.
-$0.17
EPS Surpr.
-29.4%
Revenue
$-0.00B
Q4 FY2025
Dec 19, 2025Beat
EPS Actual
-$0.22
EPS Est.
-$0.26
EPS Surpr.
+15.4%
Revenue
$-0.00B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.44
EPS Est.
-$0.42
EPS Surpr.
-4.8%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.40
EPS Est.
-$0.55
EPS Surpr.
+27.3%
Revenue
—
Q1 FY2025
Feb 14, 2025Miss
EPS Actual
-$0.89
EPS Est.
-$0.85
EPS Surpr.
-4.7%
Revenue
—
Q4 FY2024
Dec 27, 2024Beat
EPS Actual
-$0.77
EPS Est.
-$0.83
EPS Surpr.
+7.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $-0.17 | $-0.07 | $-0.01 | 1 |
| Q2 FY2027 | $-0.18 | $-0.08 | $-0.02 | 1 |
| Q1 FY2027 | $-0.19 | $-0.08 | $-0.02 | 1 |
| Q4 FY2026 | $-0.19 | $-0.08 | $-0.02 | 1 |
| Q3 FY2026 | $-0.11 | $-0.09 | $-0.05 | 3 |
| Q2 FY2026 | $-0.14 | $-0.11 | $-0.07 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -33.3% | $0.23 | $0.23 | -2.19% |
| ▼ Q1 FY2026 | Feb 17, 2026 | -29.4% | $0.49 | $0.42 | -13.82% |
| ▲ Q4 FY2025 | Dec 19, 2025 | +15.4% | $2.07 | $2.01 | -2.90% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -4.8% | $2.13 | $2.43 | +14.08% |
| ▲ Q2 FY2025 | May 15, 2025 | +27.3% | $1.75 | $1.68 | -4.00% |
| ▼ Q1 FY2025 | Feb 14, 2025 | -4.7% | $1.84 | $1.87 | +1.63% |
| ▲ Q4 FY2024 | Dec 27, 2024 | +7.2% | $1.70 | $2.01 | +18.24% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +21.7% | $7.75 | $7.34 | -5.29% |
Q2 FY2026-2.19%
Report Date
May 15, 2026
EPS Beat/Miss
-33.3%
Price Before
$0.23
Price After
$0.23
Q1 FY2026-13.82%
Report Date
Feb 17, 2026
EPS Beat/Miss
-29.4%
Price Before
$0.49
Price After
$0.42
Q4 FY2025-2.90%
Report Date
Dec 19, 2025
EPS Beat/Miss
+15.4%
Price Before
$2.07
Price After
$2.01
Q3 FY2025+14.08%
Report Date
Aug 14, 2025
EPS Beat/Miss
-4.8%
Price Before
$2.13
Price After
$2.43
Q2 FY2025-4.00%
Report Date
May 15, 2025
EPS Beat/Miss
+27.3%
Price Before
$1.75
Price After
$1.68
Q1 FY2025+1.63%
Report Date
Feb 14, 2025
EPS Beat/Miss
-4.7%
Price Before
$1.84
Price After
$1.87
Q4 FY2024+18.24%
Report Date
Dec 27, 2024
EPS Beat/Miss
+7.2%
Price Before
$1.70
Price After
$2.01
Q3 FY2024-5.29%
Report Date
Aug 14, 2024
EPS Beat/Miss
+21.7%
Price Before
$7.75
Price After
$7.34
Avg Beat Reaction+1.51%
Avg Miss Reaction-0.08%
Beat Rate4 / 8 quarters
Largest Move+18.24% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OTLK ends December
Outlook Therapeutics, Inc. (OTLK) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.16 — missing the analyst consensus of $-0.12 by -33.3%. The next OTLK earnings date is expected around September 1, 2026.
Each quarter, investors track OTLK earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OTLK revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OTLK's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OTLK earnings · 5 questionsOutlook Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. OTLK typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OTLK historically reports after market close (AMC).
OTLK earnings datewhen is OTLK earningsOTLK next earnings datewhen does OTLK report earningsOTLK earnings calendar
▸ Source: FMP · Outlook Therapeutics, Inc. SEC filings · US GAAP · Outlook Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026